Ipertas

Olmesartan medoxomil, the active ingredient in Ipertas, is a angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is indicated for the management of elevated blood pressure in adult patients. GNH USA supplies Ipertas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxomil is an antihypertensive agent that acts on the renin‑angiotensin system to lower blood pressure. - Hypertension: reduces elevated systolic and diastolic pressure in adults with high blood pressure. - Essential hypertension: provides long‑term control of blood pressure in patients with primary hypertension. - Cardiovascular risk reduction: used as part of combination therapy to help lower the risk of stroke and myocardial infarction in hypertensive patients.

Common side effects are generally mild and may resolve with continued therapy.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after the first dose. - Headache: mild to moderate headache reported by some patients. - Fatigue: feeling of tiredness or lack of energy. - Nausea: occasional upset stomach or feeling of queasiness.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue or throat requiring immediate medical attention. - Hyperkalemia: elevated potassium levels that can affect heart rhythm. - Acute renal impairment: sudden decline in kidney function, especially in patients with pre‑existing renal disease. - Hepatic injury: rare cases of liver enzyme elevation or hepatitis.

Patients should be monitored and advised before starting therapy. - Blood pressure monitoring: check regularly to ensure therapeutic effect and avoid hypotension. - Renal function assessment: evaluate serum creatinine and eGFR before and during treatment. - Electrolyte balance: monitor potassium levels, especially if combined with potassium‑sparing agents. - Pregnancy and lactation: avoid use unless clearly needed, as safety data are limited. - Hepatic impairment: use with caution in patients with severe liver disease. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Olmesartan may interact with several drug classes, requiring clinical judgement.

Major Interactions (Avoid): - Dual ACE inhibitor or ARB therapy: increased risk of renal dysfunction and hyperkalemia. - Aliskiren in diabetic patients: heightened risk of hypotension, renal impairment, and hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous elevations in serum potassium. - Lithium: concomitant use can raise lithium concentrations and toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - Thiazide diuretics: can enhance hypotensive response. - Rifampin and other CYP inducers: may reduce olmesartan plasma levels, diminishing efficacy.